Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)

Fei Li; Shou Ching Tang

doi:10.1016/j.gendis.2017.01.004

Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)

Fei Li, Shou Ching Tang

Research output: Contribution to journal › Editorial › peer-review

27 Scopus citations

Abstract

We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.

Original language	English (US)
Pages (from-to)	1-3
Number of pages	3
Journal	Genes and Diseases
Volume	4
Issue number	1
DOIs	https://doi.org/10.1016/j.gendis.2017.01.004
State	Published - Mar 1 2017
Externally published	Yes

Keywords

ANG1005
Brain metastasis
Breast cancer
LRP-1
The blood-brain-barrier

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Genetics(clinical)
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.gendis.2017.01.004

Cite this

@article{a87eebf3abab431f825a570e04505f75,

title = "Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)",

abstract = "We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.",

keywords = "ANG1005, Brain metastasis, Breast cancer, LRP-1, The blood-brain-barrier",

author = "Fei Li and Tang, {Shou Ching}",

note = "Publisher Copyright: {\textcopyright} 2017 Chongqing Medical University",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.gendis.2017.01.004",

language = "English (US)",

volume = "4",

pages = "1--3",

journal = "Genes and Diseases",

issn = "2352-4820",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)

AU - Li, Fei

AU - Tang, Shou Ching

PY - 2017/3/1

Y1 - 2017/3/1

N2 - We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.

AB - We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.

KW - ANG1005

KW - Brain metastasis

KW - Breast cancer

KW - LRP-1

KW - The blood-brain-barrier

UR - http://www.scopus.com/inward/record.url?scp=85015654049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015654049&partnerID=8YFLogxK

U2 - 10.1016/j.gendis.2017.01.004

DO - 10.1016/j.gendis.2017.01.004

M3 - Editorial

AN - SCOPUS:85015654049

SN - 2352-4820

VL - 4

SP - 1

EP - 3

JO - Genes and Diseases

JF - Genes and Diseases

IS - 1

ER -

Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this